Antihypertensive effect of manidipine

• Published in: Drugs (Basel) Vol. 65; no. Suppl 2; pp. 11 - 19
• Main Authors: ROCA-CUSACHS, Alex, TRIPOSKIADIS, Filippos
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Auckland Adis International 2005
• Subjects: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive agents; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Biological and medical sciences; Calcium Channel Blockers - therapeutic use; Cardiovascular system; Diabetes Mellitus, Type 2 - drug therapy; Dihydropyridines - adverse effects; Dihydropyridines - therapeutic use; Female; Humans; Hypertension - drug therapy; Kidney Diseases - drug therapy; Male; Medical sciences; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic; Syndrome; Human; Manidipine; Monograph; Toxicity; Calcium antagonist; Antihypertensive agent; Dihydropyridine derivatives; Review
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/00003495-200565002-00003

Manidipine is a lipophilic, third-generation, highly vasoselective, dihydropyridine (DHP) calcium channel antagonist, which, when given on a once-daily basis, effectively reduces blood pressure (BP) in patients with mild-to-moderate essential hypertension. Manidipine has a gradual onset and a long duration of action, effectively maintaining reduced BP levels throughout the 24-hour dosing period, and is effective in the long term with no evidence of intolerance. The BP-lowering capacity of manidipine is similar to that of other established DHPs and of angiotensin-converting enzyme inhibitors. Diabetic patients and very elderly patients with mild-to-moderate hypertension also respond favourably to treatment with manidipine. Manidipine has neutral effects on glucose and lipid metabolism and is generally well tolerated. Manidipine thus represents a first-line option for lowering BP in patients with mild-to-moderate hypertension.